Register now for our upcoming webinar

The website is organised and funded by PTC Therapeutics for healthcare professionals in Middle East and Africa
Patient Profiles

Select a patient profile to review

Patient 1: 5-month-old female with developmental delay and dystonia

Not a real patient. Hypothetical profile based on actual patient findings.

History and presentation1

  • Began experiencing temperature instability and problems with breastfeeding immediately after birth
  • Excessive irritability noted at 2.5 months, including being startled by noises and sudden movements
  • Oculogyric crises that began at age 3 months, typically occurring in the late afternoon or evening; with increased frequency and severity over the following 2 to 5 months
  • Axial hypotonia
  • Right-sided head deviation
  • Unable to reach for objects, roll over, or lift head while in prone position
  • Ptosis, miosis, nasal congestion, drooling
  • Treated with anti-epileptic medication, which was not effective in mitigating oculogyric crises

Imaging1

  • Brain MRI: normal

Laboratory findings1

  • Metabolic screening: normal
  • Plasma AADC activity: undetectable

CSF neurotransmitter metabolite analysis

3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydroxyindoleacetic acid; CSF, cerebrospinal fluid; HVA, homovanillic acid.
*Actual values for this patient case study were not available, so hypothetical values were added. Reference ranges vary by laboratory and patient age, and hypothetical values were based on reference ranges of <300 nmol/L for 3-OMD, 63–503 nmol/L for 5-HIAA and 176–955 nmol/L for HVA.1

References: 1. Swoboda KJ, et al. Neurology. 1999;53(6):1205–1211

Patient 2: 17-year-old male with dystonia of unclear aetiology

Not a real patient. Hypothetical profile based on actual patient findings.

History and presentation1

  • Initially diagnosed with cerebral palsy at age 6 months after presenting with feeding difficulty, hypotonia, and episodes of tongue thrusting and oculogyric crises
  • Frequency and duration of episodes increased during adolescence, occurring every 2 days and lasting up to 8 hours
  • Patient did not achieve any developmental milestones, remained nonverbal
  • Temperature instability, hypotension
  • Severe insomnia
  • Previously treated with anti-epileptic medication, which led to increased frequency of oculogyric crises and dystonic symptoms

Laboratory findings1

  • Metabolic screening: normal
  • Plasma AADC activity: undetectable

CSF neurotransmitter metabolite analysis

3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydroxyindoleacetic acid; CSF, cerebrospinal fluid; HVA, homovanillic acid.
*Actual values for this patient case study were not available, so hypothetical values were added. Reference ranges vary by laboratory and patient age, and hypothetical values were based on reference ranges of 63–503 nmol/L for 5-HIAA and 176–955 nmol/L for HVA.1

References:
1.
Swoboda KJ, et al. Neurology. 1999;53(6):1205–1211

2. Anselm IA, Darras BT. Pediatr Neurol. 2006;35(2):142–144.

Patient 1: 5-month-old female with developmental delay and dystonia

Not a real patient. Hypothetical profile based on actual patient findings.

History and presentation1

  • Began experiencing temperature instability and problems with breastfeeding immediately after birth
  • Excessive irritability noted at 2.5 months, including being startled by noises and sudden movements
  • Oculogyric crises that began at age 3 months, typically occurring in the late afternoon or evening; with increased frequency and severity over the following 2 to 5 months
  • Axial hypotonia
  • Right-sided head deviation
  • Unable to reach for objects, roll over, or lift head while in prone position
  • Ptosis, miosis, nasal congestion, drooling
  • Treated with anti-epileptic medication, which was not effective in mitigating oculogyric crises

Imaging1

  • Brain MRI: normal

Laboratory findings1

  • Metabolic screening: normal
  • Plasma AADC activity: undetectable

CSF neurotransmitter metabolite analysis

3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydroxyindoleacetic acid; CSF, cerebrospinal fluid; HVA, homovanillic acid.
*Actual values for this patient case study were not available, so hypothetical values were added. Reference ranges vary by laboratory and patient age, and hypothetical values were based on reference ranges of <300 nmol/L for 3-OMD, 63–503 nmol/L for 5-HIAA and 176–955 nmol/L for HVA.1

References: 1. Swoboda KJ, et al. Neurology. 1999;53(6):1205–1211

Patient 2: 17-year-old male with dystonia of unclear aetiology

Not a real patient. Hypothetical profile based on actual patient findings.

History and presentation1

  • Initially diagnosed with cerebral palsy at age 6 months after presenting with feeding difficulty, hypotonia, and episodes of tongue thrusting and oculogyric crises
  • Frequency and duration of episodes increased during adolescence, occurring every 2 days and lasting up to 8 hours
  • Patient did not achieve any developmental milestones, remained nonverbal
  • Temperature instability, hypotension
  • Severe insomnia
  • Previously treated with anti-epileptic medication, which led to increased frequency of oculogyric crises and dystonic symptoms

Laboratory findings1

  • Metabolic screening: normal
  • Plasma AADC activity: undetectable

CSF neurotransmitter metabolite analysis

3-OMD, 3-O-methyldopa; 5-HIAA, 5-hydroxyindoleacetic acid; CSF, cerebrospinal fluid; HVA, homovanillic acid.
*Actual values for this patient case study were not available, so hypothetical values were added. Reference ranges vary by laboratory and patient age, and hypothetical values were based on reference ranges of 63–503 nmol/L for 5-HIAA and 176–955 nmol/L for HVA.1

References:
1.
Swoboda KJ, et al. Neurology. 1999;53(6):1205–1211

2. Anselm IA, Darras BT. Pediatr Neurol. 2006;35(2):142–144.

AE-AADC-0267 | August 2022

Welcome to "About AADC MEA"

This website is provided for healthcare professionals residing in the Middle East and Africa.

This educational website provides information to support the early and accurate diagnosis of rare neurotransmitter disorders, including Aromatic L-amino Acid Decarboxylase (AADC) deficiency.